Literature DB >> 11341750

Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters.

C Durinx1, H Neels, J C Van der Auwera, K Naelaerts, S Scharpe, I De Meester.   

Abstract

In blood, the exopeptidase dipeptidyl-peptidase IV (DPPIV; EC 3.4.14.5) is predominantly present in a soluble form in plasma/serum and as an activation antigen on the membrane of lymphocytes (CD26). It modifies some important biologically active peptides (neuropeptides, chemokines), and a regulatory role for DPPIV/CD26 in immune and endocrine processes has been demonstrated. The aim of this study was to determine reference values for plasma/serum DPPIV activity and to study the association of this activity with a series of biochemical and hematological parameters and baseline characteristics such as age, gender, blood pressure and body mass index. We studied 481 healthy subjects aged between 19 and 61 years. The group consisted of 213 men and 268 women equally divided between the different categories of age. Among the women, 127 were taking hormone therapy (contraception/hormone replacement) and 141 were not. A multiple regression model shows that DPPIV activity decreases significantly with age. The activity in women is slightly lower than in men. We observed an important association with liver, muscle and lipid metabolism-related parameters. In this model, no significant contribution of body mass index, blood pressure or hormone therapy could be stated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11341750     DOI: 10.1515/CCLM.2001.026

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  21 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

2.  Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study.

Authors:  L D Carbone; P Bůžková; H A Fink; J A Robbins; M Bethel; C M Isales; W D Hill
Journal:  Osteoporos Int       Date:  2017-02-02       Impact factor: 4.507

Review 3.  BNP molecular forms and processing by the cardiac serine protease corin.

Authors:  Tomoko Ichiki; Brenda K Huntley; John C Burnett
Journal:  Adv Clin Chem       Date:  2013       Impact factor: 5.394

4.  Association of CD26/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis.

Authors:  Farshid Yeganeh; Seyed Mohammad Javad Mousavi; Saeed Hosseinzadeh-Sarband; Arman Ahmadzadeh; Hooman Bahrami-Motlagh; Mostafa Haji Molla Hoseini; Mandana Sattari; Mohammad Reza Sohrabi; Ramin Pouriran; Pooneh Dehghan
Journal:  Clin Rheumatol       Date:  2018-08-22       Impact factor: 2.980

5.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.

Authors:  E Mannucci; L Pala; S Ciani; G Bardini; A Pezzatini; I Sposato; F Cremasco; A Ognibene; C M Rotella
Journal:  Diabetologia       Date:  2005-04-29       Impact factor: 10.122

6.  Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.

Authors:  Carmen Wolke; Alexander Teumer; Karlhans Endlich; Nicole Endlich; Rainer Rettig; Sylvia Stracke; Beate Fiene; Simone Aymanns; Stephan B Felix; Anke Hannemann; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-30

7.  Distribution of dipeptidyl peptidase IV in patients with chronic tonsillitis.

Authors:  Milan Stankovic; Predrag Vlahovic; Verica Avramovic; Miroljub Todorovic
Journal:  Clin Vaccine Immunol       Date:  2008-04-02

8.  Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.

Authors:  Arpi Nazarian; Kevin Lawlor; San San Yi; John Philip; Mousumi Ghosh; Mariana Yaneva; Josep Villanueva; Alan Saghatelian; Melissa Assel; Andrew J Vickers; James A Eastham; Howard I Scher; Brett S Carver; Hans Lilja; Paul Tempst
Journal:  Mol Cell Proteomics       Date:  2014-07-23       Impact factor: 5.911

9.  Aminopeptidase activities as prospective urinary biomarkers for bladder cancer.

Authors:  Jennifer M Taylor; Mariana Yaneva; Kevin Velasco; John Philip; Hediye Erdjument-Bromage; Irina Ostrovnaya; Hans G Lilja; Bernard H Bochner; Paul Tempst
Journal:  Proteomics Clin Appl       Date:  2014-03-31       Impact factor: 3.494

10.  Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.

Authors:  Ivana Z Matić; Marija Ðorđić; Nađa Grozdanić; Ana Damjanović; Branka Kolundžija; Aleksandra Erić-Nikolić; Radan Džodić; Miomir Šašić; Srđan Nikolić; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Dušica Gavrilović; Oscar J Cordero; Zorica D Juranić
Journal:  BMC Immunol       Date:  2012-08-21       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.